{"id":"anti-il17","safety":{"commonSideEffects":[{"rate":"10%","effect":"Injection site reaction"},{"rate":"8%","effect":"Headache"},{"rate":"5%","effect":"Nausea"}]},"_chembl":{"chemblId":"CHEMBL2108941","moleculeType":"Unknown"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Anti-IL17 drugs target the interleukin-17 cytokine, which plays a key role in inflammatory responses.","oneSentence":"IL-17 inhibitor","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T04:09:59.510Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Psoriasis"},{"name":"Plaque psoriasis"}]},"trialDetails":[{"nctId":"NCT07234838","phase":"","title":"Effect of Anti-Psoriatic Biologics on Risk of Anogenital Warts (CONDYPSO)","status":"RECRUITING","sponsor":"Jonathan Krygier","startDate":"2026-02-01","conditions":"Psoriasis, Condyloma Acuminata, Biotherapies","enrollment":600},{"nctId":"NCT07237594","phase":"PHASE1","title":"IL-17 Blockade to Decrease irAEs (REPLAY)","status":"NOT_YET_RECRUITING","sponsor":"Duke University","startDate":"2026-05-01","conditions":"Metastatic Melanoma","enrollment":4},{"nctId":"NCT06993610","phase":"PHASE2","title":"Tibulizumab Skin Healing and Inflammation Evaluation for Lasting Defense","status":"RECRUITING","sponsor":"Zura Bio Inc","startDate":"2025-05-16","conditions":"Hidradenitis Suppurativa (HS)","enrollment":225},{"nctId":"NCT06843239","phase":"PHASE2","title":"Tibulizumab Systemic Sclerosis Understanding and Response Evaluation (TibuSURE)","status":"RECRUITING","sponsor":"Zura Bio Inc","startDate":"2025-02-06","conditions":"Systemic Sclerosis (SSc), Scleroderma","enrollment":80},{"nctId":"NCT04306315","phase":"PHASE4","title":"Adjusted Brodalumab Dose Compared With Standard Brodalumab Dose in Subjects With Moderate-to-severe Plaque Psoriasis and ≥120 kg Body Weight","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2022-08-16","conditions":"Psoriasis Vulgaris","enrollment":385},{"nctId":"NCT04899154","phase":"NA","title":"Analysis of Intestinal Microbiota as a Predictor of Response to Treatment of Spondyloarthritis With Biotherapy","status":"RECRUITING","sponsor":"Hôpital Européen Marseille","startDate":"2019-07-16","conditions":"Spondyloarthritis","enrollment":80},{"nctId":"NCT04520048","phase":"NA","title":"Vascular Biomarkers Predictive of the Progression From Hypertensive Disorders in Pregnancy to Preeclampsia in Pregnant Women","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2023-08-11","conditions":"Hypertension Disorders in Pregnancy, Gestational Hypertension, Pre-Eclampsia","enrollment":110},{"nctId":"NCT07021495","phase":"","title":"SKIN Disease Profiling by an Exploratory, pRospective, Biomarker Study in dermatoloGY Practice (SKINERGY)","status":"RECRUITING","sponsor":"Leiden University Medical Center","startDate":"2025-07-29","conditions":"Chronic Spontaneous Urticaria (CSU), Hidradenitis Suppurativa (HS), Psoriasis (PsO)","enrollment":840},{"nctId":"NCT03358693","phase":"","title":"Molecular Signatures in Inflammatory Skin Disease","status":"RECRUITING","sponsor":"Prof. Dr. Stephan Weidinger","startDate":"2017-01-20","conditions":"Atopic Dermatitis, Psoriasis","enrollment":300},{"nctId":"NCT03598751","phase":"PHASE3","title":"Clinical Study of Efficacy and Safety of BCD-085 (Monoclonal Anti-IL-17 Antibody) in Psoriatic Arthritis","status":"COMPLETED","sponsor":"Biocad","startDate":"2018-07-25","conditions":"Psoriatic Arthritis","enrollment":194},{"nctId":"NCT07041112","phase":"","title":"Ten-Year Biologic Drug Survival in Psoriasis: Role of Genetic and Cardiometabolic Predictors","status":"COMPLETED","sponsor":"Juan Ruano Ruiz","startDate":"2012-01-01","conditions":"Psoriasis, Psoriatic Arthritis (PsA), Cardiovascular Risk Factors","enrollment":1000},{"nctId":"NCT06399432","phase":"NA","title":"Mediterranean Diet vs no Dietary Intervention for Improving Signs and Symptoms of Psoriasis in Patients Treated With Anti-IL-17 or Anti-IL-23 Inhibitors","status":"RECRUITING","sponsor":"University Hospitals Cleveland Medical Center","startDate":"2022-10-18","conditions":"Psoriasis","enrollment":36},{"nctId":"NCT05111210","phase":"","title":"Exploration of the Cellular and Molecular Mechanisms in Patients Receiving Biotherapies Targeting the IL-23/IL-17 Axis in Cutaneous Psoriasis","status":"RECRUITING","sponsor":"Institut Pasteur","startDate":"2021-12-14","conditions":"Psoriasis","enrollment":90},{"nctId":"NCT05812157","phase":"NA","title":"Optimizing Anti-IL17 Antibody Therapy by Associating Fiber Supplementation to Correct Treatment-aggravated Gut Dysbiosis in Axial Spondyloarthritis - RESPOND-IL17","status":"RECRUITING","sponsor":"Centre Hospitalier Universitaire de Nīmes","startDate":"2023-10-02","conditions":"Axial Spondyloarthritis","enrollment":36},{"nctId":"NCT06918886","phase":"","title":"Comparison of Liver Health in Psoriatic Arthritis Patients Using Anti-TNF or Anti-IL17 Treatments","status":"NOT_YET_RECRUITING","sponsor":"Bezmialem Vakif University","startDate":"2025-04-10","conditions":"Psoriatic Arthritis (PsA), Liver Fibrosis, Liver Diseases","enrollment":90},{"nctId":"NCT05054361","phase":"","title":"Crosstalk Between Mucosal-Associated Invariant T (MAIT) Cells and the Gut Microbiota and Mucosa in the Development of Type 1 Diabetes in Children","status":"RECRUITING","sponsor":"Institut National de la Santé Et de la Recherche Médicale, France","startDate":"2022-01-01","conditions":"Type1diabetes","enrollment":180},{"nctId":"NCT06224634","phase":"","title":"The Effect of Anti-IL17 on Airway Hyperresponsiveness and Resistance","status":"RECRUITING","sponsor":"Copenhagen University Hospital, Hvidovre","startDate":"2024-08-02","conditions":"Asthma","enrollment":74},{"nctId":"NCT04589325","phase":"PHASE2","title":"Ixekizumab Diabetes Intervention Trial (I-DIT)","status":"RECRUITING","sponsor":"Göteborg University","startDate":"2022-11-09","conditions":"Type1 Diabetes Mellitus","enrollment":127},{"nctId":"NCT06642207","phase":"","title":"Effect of IL17 Inhibitor in Comparison With Anti-TNF in Patients With Ankylosing Spondylitis","status":"RECRUITING","sponsor":"Sohag University","startDate":"2024-10-01","conditions":"Ankylosing Spondylitis","enrollment":50},{"nctId":"NCT04347798","phase":"","title":"IMPACT: IMPact of Antimalarials on Covid-19 Infections in RAPPORT","status":"COMPLETED","sponsor":"University of Alberta","startDate":"2020-11-01","conditions":"Covid-19 Infection, Rheumatoid Arthritis, Psoriatic Arthritis","enrollment":773},{"nctId":"NCT04237116","phase":"PHASE3","title":"A Study of Secukinumab Treatment in Patients With Plaque Psoriasis and Coexisting Non-alcoholic Fatty Liver Disease (NAFLD)","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2020-02-19","conditions":"Plaque Psoriasis, Non-alcoholic Fatty Liver Disease","enrollment":10},{"nctId":"NCT06055699","phase":"","title":"Association Between the Occurrence of a Clinical RElapse and Gut MIcrobiota Modifications: a Cohort Study of Patients With pSOriasis","status":"NOT_YET_RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2024-03-01","conditions":"Psoriasis, Microbial Colonization","enrollment":50},{"nctId":"NCT05957120","phase":"","title":"Subclinical Impairment of Cardiovascular System in Patients With Psoriasis","status":"COMPLETED","sponsor":"University Medical Centre Ljubljana","startDate":"2022-01-03","conditions":"Psoriasis, Inflammation, Endothelial Dysfunction","enrollment":100},{"nctId":"NCT02144857","phase":"PHASE4","title":"Effects of Treatment With Biological Agents on Vascular and Cardiac Function in Psoriasis","status":"UNKNOWN","sponsor":"University of Athens","startDate":"2014-05-30","conditions":"Psoriasis","enrollment":200},{"nctId":"NCT05696106","phase":"","title":"Risk of Incident IMID in Patients Treated With Biologics and Immunosuppressive Drugs for a Single IMID","status":"UNKNOWN","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2023-04-02","conditions":"Inflammatory Disease","enrollment":750000},{"nctId":"NCT02733094","phase":"PHASE1, PHASE2","title":"Single-arm Study to Assess a Potential Effect of Anti-IL-17 (Secukinumab) in the Treatment of Pyoderma Gangrenosum","status":"COMPLETED","sponsor":"Technical University of Munich","startDate":"2016-04","conditions":"Pyoderma Gangrenosum","enrollment":8},{"nctId":"NCT02620189","phase":"","title":"Th17 Responses Evaluated in RA Patients on Inhibitors of TNFα","status":"COMPLETED","sponsor":"Queen Mary University of London","startDate":"2015-03","conditions":"Rheumatoid Arthritis","enrollment":60},{"nctId":"NCT03690544","phase":"PHASE4","title":"Apremilast for RAS","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2018-10-12","conditions":"Recurrent Aphthous Stomatitis","enrollment":15},{"nctId":"NCT05344482","phase":"","title":"Evaluation of the Effectiveness of Secukinumab in Patients With Moderate to Severe Plaque Psoriasis","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2020-07-09","conditions":"Plaque Psoriasis","enrollment":277},{"nctId":"NCT05244109","phase":"NA","title":"Biomedicines and Bacterial Translocation in Spondyloarthritis","status":"UNKNOWN","sponsor":"Centre Hospitalier Universitaire de Besancon","startDate":"2022-02-07","conditions":"Axial Spondyloarthritis","enrollment":90},{"nctId":"NCT05302947","phase":"","title":"COVID-19 Study at the Russian Clinical and Research Center of Gerontology of the Pirogov RNRMU","status":"COMPLETED","sponsor":"Pirogov Russian National Research Medical University","startDate":"2020-02-01","conditions":"COVID-19, Mild to Moderate","enrollment":154},{"nctId":"NCT01364389","phase":"PHASE2","title":"A 3-arm Proof of Concept Study of AIN457, ACZ885 or Corticosteroids in Patients With Polymyalgia Rheumatica","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2011-02-14","conditions":"Polymyalgia Rheumatica, Inflammatory Diseases","enrollment":16},{"nctId":"NCT01009281","phase":"PHASE2","title":"An Open Label Safety and Tolerability Study of AIN457 in Patients With Moderate to Severe Crohn's Disease","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2009-10-30","conditions":"Crohn's Disease, Inflammatory Bowel Disease","enrollment":7},{"nctId":"NCT01109940","phase":"PHASE2","title":"Safety and Tolerability of AIN457 in Adults (18-65 Years) With Moderate to Severe Ankylosing Spondylitis","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2010-04","conditions":"Ankylosing Spondylitis","enrollment":39},{"nctId":"NCT01169844","phase":"PHASE2","title":"Safety and Tolerability of AIN457 in Adults (18-65 Years) With Psoriatic Arthritis","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2010-06","conditions":"Psoriatic Arthritis","enrollment":28},{"nctId":"NCT01539213","phase":"PHASE1","title":"Distribution of Secukinumab (AIN457) Into Dermal Interstitial Fluid After a Single Subcutaneous Administration of 300 mg","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2012-02","conditions":"Healthy, Psoriasis","enrollment":16},{"nctId":"NCT03073213","phase":"PHASE1","title":"A Study of Ixekizumab in Chinese Participants With Psoriasis Vulgaris","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2017-04-13","conditions":"Psoriasis","enrollment":32},{"nctId":"NCT01107457","phase":"PHASE2","title":"A Study in Participants With Moderate to Severe Psoriasis","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2010-04","conditions":"Psoriasis","enrollment":142},{"nctId":"NCT03154762","phase":"NA","title":"Anti-inflammatory Effect of Nocturnal NIPPV on Acute Asthma","status":"COMPLETED","sponsor":"National Institute of Respiratory Diseases, Mexico","startDate":"2017-06-01","conditions":"Asthma Acute","enrollment":20},{"nctId":"NCT03358134","phase":"PHASE3","title":"Mechanism of Action of Anti-IL17 Therapy in Peripheral Spondyloarthritis","status":"COMPLETED","sponsor":"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","startDate":"2014-03","conditions":"Spondylarthropathies","enrollment":20},{"nctId":"NCT01377012","phase":"PHASE3","title":"Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Anti-TNFα Agents","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2011-08-30","conditions":"Rheumatoid Arthritis","enrollment":637},{"nctId":"NCT02883894","phase":"","title":"Interest of Dosage of Anti-PB230, Anti-PB180 and Cytokines for Monitoring of Patients Suffering From Bullous Pemphigoid","status":"COMPLETED","sponsor":"CHU de Reims","startDate":"2009-11","conditions":"Bullous Pemphigoid","enrollment":120},{"nctId":"NCT01770379","phase":"PHASE3","title":"Secukinumab Efficacy and Safety Study in Patients With Rheumatoid Arthritis and Inadequate Response to Anti-TNFα Agents.","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2012-10","conditions":"Rheumatoid Arthritis","enrollment":242},{"nctId":"NCT00966875","phase":"PHASE2","title":"A Study in Patients With Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2009-08","conditions":"Rheumatoid Arthritis","enrollment":448},{"nctId":"NCT01350804","phase":"PHASE3","title":"Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis (RA) and an Inadequate Response to Anti-Tumor Necrosis Factor α (Anti-TNFα) Agents (CAIN457F2309 and CAIN457F2309E1)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2011-09","conditions":"Rheumatoid Arthritis","enrollment":551},{"nctId":"NCT02778711","phase":"PHASE3","title":"Anti-IL-17 a New Treatment for Contact Dermatititis","status":"UNKNOWN","sponsor":"Tanja Todberg, MD","startDate":"2016-01","conditions":"Allergic Contact Dermatitits","enrollment":20},{"nctId":"NCT00936585","phase":"NA","title":"NIH Substudy of AIN457 (Anti-IL-17 Monoclonal Antibody) for Treatment of Moderate to Severe Crohn's Disease","status":"TERMINATED","sponsor":"National Institutes of Health Clinical Center (CC)","startDate":"2009-07","conditions":"Colitis, Crohn's Disease, Inflammatory Bowel Disease","enrollment":2},{"nctId":"NCT00584740","phase":"PHASE2","title":"Efficacy, Safety and Tolerability of AIN457 in Moderate to Severe Active Crohn's Disease","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2008-08","conditions":"Crohn's Disease","enrollment":59},{"nctId":"NCT00860691","phase":"NA","title":"Double Blinded Randomized Clinical Trial of the Effect of Open Versus Laparoscopic Colectomy on Neutrophils in Patients With Colon Cancer","status":"UNKNOWN","sponsor":"University Hospital Dubrava","startDate":"2008-01","conditions":"Colonic Neoplasms","enrollment":60}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":178,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"Anti-IL17","genericName":"Anti-IL17","companyName":"Prof. Dr. Stephan Weidinger","companyId":"prof-dr-stephan-weidinger","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Anti-IL17 has been studied in clinical trials for various skin conditions, including Chronic Spontaneous Urticaria, Hidradenitis Suppurativa, Psoriasis, Atopic Dermatitis, and CTCL/ Mycosis Fungoides. The treatment has been investigated in combination with Ixekizumab, a monoclonal antibody targeting IL17, and has also been compared to a placebo in clinical trials.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}